食铁通过DNA甲基化重塑减轻表观遗传衰老,并延长老年人的生存期
Jia-Jun Zhao1,2, Jianghua Zhang1,2, Siyan Li1,3
1College of Food and Health, Zhejiang A&F University, Hangzhou, Zhejiang, China.
Clinical epigenetics
|October 30, 2025
概括
饮食中铁的摄入量较高与表观遗传衰老的减缓以及老年人死亡风险的降低有关. 优化铁摄入量可能通过影响DNA甲基化标记物来促进更健康的衰老.
科学领域:
- 营养流行病学 营养流行病学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 老年学是一门学科.
背景情况:
- 铁平衡对于生物功能至关重要,但其在表观遗传衰老和死亡率中的作用尚不清楚.
- 饮食中的铁对DNA甲基化 (DNAm) 的影响及其对死亡结果的调解需要研究.
研究的目的:
- 为了检查饮食中的铁摄入量与老年人DNAm衰老标志物之间的关联.
- 确定表观遗传特征是否调解铁摄入量与死亡率之间的关系.
主要方法:
- 从NHANES (1999-2002) 分析了2,398名年龄≥50岁的成年人,死亡率随访长达20年.
- 通过24小时召回和使用Illumina MethylationEPIC BeadChip的DNA甲基化概况来评估饮食中的铁摄入量.
- 应用回归和调解分析来识别对铁有反应的DNAm特征并量化表观遗传途径.
主要成果:
- 饮食中较高的铁摄入量与有利的表观遗传特征相关,包括降低死亡率预测DNAm标志物的水平,如GrimAge2Mort.
- 对铁有反应的DNAm特征显著预测了全因和因特定死亡率.
- 增加铁的摄入量与所有原因,心脏病和呼吸系统疾病的死亡率降低直接相关.
结论:
- 饮食中的铁摄入量是影响老年人表观遗传衰老和死亡风险的可改变因素.
- 表观遗传重新校准显著介导铁对死亡率的保护作用.
- 优化铁摄入量是促进健康衰老的潜在营养策略.
相关概念视频
01:37Epigenetic Regulation
3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.7K
01:46Epigenetic Regulation
33.4K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.4K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
182
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
182
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
229
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
229
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
192
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
192
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
224
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
224